128 related articles for article (PubMed ID: 17045090)
1. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
[TBL] [Abstract][Full Text] [Related]
2. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin inhibition.
Dutcher JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6382S-7S. PubMed ID: 15448035
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
6. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
9. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.
Drakos E; Rassidakis GZ; Medeiros LJ
Expert Rev Mol Med; 2008 Feb; 10():e4. PubMed ID: 18241520
[TBL] [Abstract][Full Text] [Related]
11. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
12. Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM; Eisen T
Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
[TBL] [Abstract][Full Text] [Related]
14. The biology behind mTOR inhibition in sarcoma.
Wan X; Helman LJ
Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
[TBL] [Abstract][Full Text] [Related]
15. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
16. Renal cell cancer.
Hutson TE; Figlin RA
Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
MacKenzie AR; von Mehren M
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
19. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]